Every biopharma leader knows drug development is expensive—but the magnitude deserves emphasis because it directly shapes the urgency around launch readiness.
The average therapy takes 10–15 years¹ to travel from early discovery to final approval. The cost of that journey, depending on methodology, typically ranges from $1.1 and $2.6 billion² once failures are included. Decades of work and billions in investment hinge on a single, critical moment: the product launch.
Unlike larger organizations, emerging biopharmas often have:
